Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb;84(2):248-288.
doi: 10.1016/j.jinf.2021.09.019. Epub 2021 Sep 30.

Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study

A Atti  1 , M Ferrari  2 , J Castillo-Olivares  2 , E J M Monk  3 , R Gopal  3 , M Patel  3 , K Hoschler  3 , M J Cole  3 , A Semper  4 , J Hewson  4 , A D Otter  4 , S Foulkes  3 , J Islam  3 , M Mirfenderesky  5 , S Jain  5 , J Murira  6 , C Favager  6 , E Nastouli  7 , M A Chand  3 , C S Brown  3 , J L Heeney  2 , T Brooks  4 , V J Hall  3 , S Hopkins  3 , M Zambon  3
Affiliations
Comment

Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study

A Atti et al. J Infect. 2022 Feb.
No abstract available

Keywords: COVId-19; COVId-19 serological testing; Neutralising antibodies; Reinfection; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declarations of Competing Interest None.

Figures

Fig. 1
Fig. 1
Serological response in Case 1 and Case 2 against SARS-CoV-2, including anti-N, anti-S, anti-RDB and neutralising antibodies. Vertical dashlines represent the reinfection events for Case 1 (red) and Case 2 (blue). Horizontal dashline represents cutoff values. (a) Anti-SARS-CoV-2 nucleocapsid (N) protein assay (Roche Diagnostics - Cutoff ≥ 1.0 U/mL). (b) Fully quantitative Elecsys Anti-SARS-CoV-2 spike (S) protein assay (Roche Diagnostics - Cutoff ≥ 0.8 U/mL). (c) In-house recombinant SARS-CoV-2 IgG spike (S) protein receptor binding domain (RBD) indirect ELISA (Cutoff ≥ 5.0). (d) Neutralising antibodies were detected using a live virus microneutralisation assay, using England/2/2020 virus (Cutoff ≥ 20.0).
Fig. 2
Fig. 2
Immuno-blotting of Case 1 (a) and Case 2 (b) plasma samples showing the reactivity of IgG (left), IgA (middle) and IgM (right) against the Spike, S1, S2, N and RBD antigens of SARS-CoV-2. Dashed lines represent the reinfection events.
See this image and copyright information in PMC

Comment on

References

    1. Hanrath A.T., Payne B.A.I., Duncan C.J.A. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. J Infect. 2021;82(4):e29–e30. - PMC - PubMed
    1. Sariol A., Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity. 2020;53(2):248–263. - PMC - PubMed
    1. Edridge A.W.D., Kaczorowska J., Hoste A.C.R., Bakker M., Klein M., Loens K., et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26(11):1691–1693. - PubMed
    1. Wallace S., Hall V., Charlett A., Kirwan P.D., Cole M.J., Shrotri M., et al. SIREN protocol: impact of detectable anti-SARS-CoV-2 on the subsequent incidence of COVID-19 in 100,000 healthcare workers: do antibody positive healthcare workers have less reinfection than antibody negative healthcare workers? medRxiv. 2020;2020 doi: 10.1101/2020.12.15.20247981. - DOI
    1. Manisty C., Otter A.D., Treibel T.A., McKnight Á., Altmann D.M., Brooks T., et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057–1058. - PMC - PubMed

Substances

LinkOut - more resources